Investment

Barcelona, [July 2nd, 2025] — The Board of Directors of Peptomyc S.L., a pioneering biotech company developing innovative cancer therapies targeting the MYC oncoprotein, is pleased to announce a strategic leadership transition aimed at accelerating the company’s business development and clinical expansion efforts. Effective July 2nd, 2025, Jesus Martin Garcia will assume the role of Chief Executive Officer (CEO). Jesus brings a strong track record in business development, strategic partnerships, and company scaling across…

Round co-led by Columbus Venture Partners, Panakès Partners and Mérieux Equity Partners Barcelona, Spain – 29 April 2025 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today the successful closing of an oversubscribed Series C financing round, raising €50 million. The round was co-led by prominent investors Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners. The financing round also had strong participation from…

Accure to complete required preclinical studies to file IND application for ACT-02 program in 2026 Fonds National de Recherche (FNR) grant will fund Transcend-PD project, designed to evaluate efficacy of ACT-02 in translational iPSC models, to support patient selection and stratification Funding marks significant support for Accure’s asset, which should enter clinical development in 2026 Barcelona, Spain, April 7, 2025 – Accure Therapeutics, a private translational neuroscience R&D company, today…

Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on eliminating hard-to-treat resistant cancer cells Barcelona, Spain, 19 February 2025: Ona Therapeutics (“Ona”), a global…

You can read more here: https://www.peptomyc.com/peptomyc-announces-the-beginning-of-a-phase-2-clinical-trial-of-omo-103-in-advanced-osteosarcoma/

Phase 2 trial with lead neuroprotective molecule OCS-05 (formerly ACT-01) completed by licensing partner Oculis met primary safety endpoint and key secondary efficacy endpoints with no serious adverse events Trial success clearly supports Accure’s translational approach to drug development and partnership business model Accure has two other assets in the pipeline to treat range of central nervous system (CNS) disorders You can read the whole new here: https://accure.health/accure-therapeutics-partner-oculis-reached-positive-phase-2-results-for-lead-neuroprotective-therapy/

Full press release here: https://www.peptomyc.com/peptomyc-announces-research-ind-approval-for-innovative-window-of-opportunity-trial-in-collaboration-with-ohsu-knight-cancer-institute-portland-oregon-usa-in-pdac-patients/

deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test Full post here: https://www.globenewswire.com/news-release/2024/12/02/2989457/0/en/deepull-receives-FDA-Breakthrough-Device-Designation-for-its-UllCORE-Bloodstream-Infection-Test.html

VC funding led by imec.xpand, with significant participation from the EIC Fund (venture arm of the European Innovation Council) and continued support from existing investors Asabys Partners and Aliath Bioventures. Funding will be used to advance clinical trials for BCI therapeutics and support the team expansion to accelerate development and commercialization. More information here: https://www.businesswire.com/news/home/20241029660063/en/INBRAIN-Neuroelectronics-Raises-50M-Series-B-to-Advance-Graphene-Based-Brain-Computer-Interface-Technology

You can read full information here:https://www.manchester.ac.uk/about/news/inbrain-neuroelectronics-announces-worlds-first-human-graphene-based-brain-computer-interface-procedure/